1. Introduction
Approximately 50% of acute coronary syndromes (ACS) arise from the rupture of non-occlusive coronary lesions [1,2]. Many of these lesions have features which predispose them to rupture and are termed high-risk plaques (HRP). Coronary computed tomography angiography (CTA) is a widely used non-invasive imaging modality which can reliably assess HRP features [3]. Importantly, the presence of HRP in patients with stable coronary artery disease (CAD) is associated with an increased prospective risk of ACS [4,5], highlighting the potential prognostic value of HRP detection on imaging.
Chronic vascular inflammation plays a key role in atherogenesis and atherosclerotic plaque rupture. Pericoronary adipose tissue (PCAT) attenuation is a novel marker of coronary inflammation on coronary CTA, capturing changes in adipocyte size and lipid accumulation caused by inflammatory mediators from the vascular wall [6]. Measurement of PCAT around the proximal RCA represents a standardised and prognostically validated per-patient metric [7,8,9,10]. PCAT attenuation can also be quantified around identifiable coronary lesions as a dynamic marker of coronary inflammation [6,7,11]. While increased PCAT attenuation has been reported surrounding HRP [12,13,14], few studies have systematically evaluated the association between ACS and PCAT attenuation in patients with HRP. We sought to perform a per-patient and per-lesion level analysis of PCAT attenuation in stable CAD patients with HRP who develop subsequent ACS.
2. Materials and Methods
2.1. Patients
A cohort of 1254 consecutive patients with available follow-up data, referred for coronary CTA between September 2008 and November 2017, was retrospectively collected. Stable CAD was defined as stable angina with no prior history of CAD. We excluded patients with poor scan quality as assessed by a five-point Likert scale [15] and those who underwent early revascularisation (<3 months). Patients were followed up for long-term outcomes until November 2017. Patients’ follow-up was a median of 5.3 years (IQR 5.1 years to 5.7 years). Two independent cardiologists blinded to patient data adjudicated the presence of HRP and ACS. Presence of HRP was determined via visual evaluation of coronary CTA images for HRP characteristics. ACS was defined as per the basis of the third universal definition of myocardial infarction with or without ST elevation (STEMI and NSTEMI, respectively) alongside troponin elevation, and unstable angina, assessed using a combination of medical records, blood results and findings on invasive angiography [16]. ACS, late unplanned revascularisation (>3 months from coronary CTA) and cardiac death were study endpoints. Three patients with ACS died from cardiac causes. This study was approved by the Monash Health Human Research Ethics Committee.
2.2. Coronary CTA Protocol
Coronary CTA scans were performed using a 320-detector row scanner (Aquilion ONE; Canon Medical Systems Corporation, Otawara, Japan). Acquisitions were obtained during a single breath-hold with prospective ECG triggering, with use of beta-blockers for heart rate control at 60 bpm when required. Coronary CTA acquisition parameters were: detector configuration 320 × 0.5 mm; tube current 300–500 mA (depending on body mass index (BMI)); tube potential 100–120 kV; gantry rotation time 275 ms; and temporal resolution 175 ms. Iodinated contrast was administered (60–90 mL, 350 mg iodine per mL (Omnipaque)) at a rate of 5 mL/s. Image reconstruction was mediated by the adaptive iterative dose-reduction three-dimensional algorithm (AIDR3D, Canon Medical Systems) and FC43 reconstruction kernel to generate a 512 × 512 matrix with 0.5 mm slice thickness and 0.25 mm slice increments.
2.3. Plaque Analysis
HRP was identified via visual assessment by two independent experts blinded to both patient demographics and clinical data (RM, DW). HRP was defined as the presence of at least two of the following features: positive remodelling (PR), low-attenuation plaque (LAP) or spotty calcification (SC). These features have been defined previously [4,17]. Briefly, PR was assessed by comparison of vessel diameter at the coronary lesion to diameter at a reference site proximal to the lesion. This ratio was quantified as a remodelling index (lesion diameter/reference diameter). If the lesion diameter was ≥10% larger than the reference segment, the lesion was defined as positively remodelled. LAP was defined as plaque attenuated at <30 HU. SC was defined on both multiplanar reconstructed images as calcification <3 mm, and on cross-sectional images as calcification covering <90° of the vessel arc. Obstructive CAD was defined on visual assessment as >50% diameter stenosis.
Semi-automated software (Vitrea 6 Version 3.0 with SUREPlaque; Vital Images and Canon Medical Systems) was used to quantify total plaque volume, vessel and plaque diameter and plaque attenuation. Total plaque burden per lesion was calculated as: (total plaque volume/total vessel volume) × 100. CAD severity was also assessed by segment involvement score (SIS) and segment stenosis score (SSS). SIS refers to the total number of coronary segments with plaque, while SSS refers to the total stenosis score in each segment according to a five-point scale: 0, 0% stenosis (normal); 1, 1–24% stenosis (minor); 2, 25–49% stenosis (mild); 3, 50–69% stenosis (moderate); 4, 70–99% stenosis (severe) [18,19].
2.4. PCAT Analysis
PCAT was quantified in each patient around the proximal right coronary artery (PCATRCA) and around specific identified lesions (PCATLesion)—culprit coronary lesions in patients with ACS, and the highest-grade stenosis lesions in patients with HRP without ACS and in controls, using semi-automated software (AutoPlaque v2.5, Cedars-Sinai Medical Centre, Los Angeles, CA, USA). Using this software, an experienced operator blinded to clinical data (JY) applied a centreline to the vessel containing the target plaque and demarcated adventitia from surrounding adipose tissue. Adipose tissue was defined as all voxels between −190 HU and −30 HU within a predefined volume of interest. This volume of interest included three-dimensional concentric layers extending outward from the operator-traced vessel wall to an extent of 3 mm, the typical diameter of the RCA [11]. PCAT was automatically quantified as the mean attenuation of all voxels within this volume. Analysis excluded all non-adipose tissue and vessel branches not delineated by the manually defined centreline and vessel wall.
PCATRCA is a standardised technique that provides information on the inflammatory status of the entire coronary tree and is measured in the proximal 10–50 mm of the RCA, a method which has been validated previously [6,7,8]. PCATLesion was measured around target lesions, with the proximal and distal borders of the analysis region defined as the proximal and distal ends of the lesion [6,12,14].
2.5. Statistical Analysis
The patient selection process is summarised in Figure 1. Of the 1254 patients, 243 patients with HRP were propensity-matched on a 1:1 basis to patients without HRP using a nearest-neighbour approach. Propensity-matching was performed on the basis of age, sex, hypertension, hypercholesterolaemia, diabetes mellitus, current smoking status and family history of ischaemic heart disease (IHD). Patients were excluded on the basis of poor scan quality or the use of dated scan parameters (n = 82, 16.9%). Scan quality was assessed via a five-point Likert score as described previously [15]. Differences in scan parameters within the initial cohort included iterative reconstruction algorithm, reconstruction kernel and the scanner itself. Only scans performed between 2011 and 2016 were included to maintain consistency in scan parameters between patients with HRP and controls. A total of 41 patients with HRP matched to 41 patients without HRP with coronary CTA being performed between 2011 and 2016 were investigated.
Data were tested for normality using the Shapiro–Wilk test. Continuous variables are presented as mean ± standard deviation or median (interquartile range/IQR), as appropriate. Comparison of continuous variables between groups was assessed using the independent t-test. A Chi-square or Fisher’s exact test was used for categorical variables. The relationship between PCAT attenuation and age, sex and individual cardiovascular risk factors (hypertension, hypercholesterolaemia, diabetes mellitus, smoking, family history of IHD) was assessed using linear regression. Binary logistic regression was used to assess the relationship between the presence of HRP and PCATRCA, correcting for the aforementioned covariates. Variables with a p < 0.20 on univariable analyses were included in multivariable models, and a two-sided p-value < 0.05 was considered statistically significant. Additionally, univariable Cox regression analysis was performed to determine the odds of ACS development against covariates found to be significant in logistic regression analysis. The censoring period for this analysis was defined as the date of coronary CTA to the time of ACS, or the date of follow-up in patients who did not present with ACS. All statistical analyses were performed using IBM SPSS Statistics (version 25).
3. Results
Baseline patient characteristics are summarised in Table 1. The final study population comprised 82 patients; mean age was 59.5 ± 9.7 years and 67% were males. Patients with HRP were well-matched to non-HRP patients in terms of age, sex and cardiovascular risk factors. Median time to ACS was 1.9 years (IQR 1.3 years to 4.2 years). ACS was more frequent in patients with HRP compared to controls, but this was not significant (24.4% (n = 10) vs. 7.3% (n = 3), p = 0.07).
3.1. Plaque and Vessel Characteristics
All patients with HRP had PR, with a median remodelling index of 1.5 (IQR, 1.31 to 1.73). Furthermore, LAP was present in 58.5% (n = 24) and SC was present in 53.7% (n = 22) of HRP patients. Obstructive CAD was observed in a small proportion of patients with HRP (36.6%, n = 15), and in one control patient (2.44%). Compared to patients without HRP, patients with HRP had a higher median SIS (4.5 (IQR 3 to 6) vs. 1.0 (IQR 0 to 4.5), p < 0.001) and SSS (5.5 (IQR 3 to 9.5) vs. 2.0 (IQR 0 to 6), p = 0.001 (Table 1)).
3.2. Relationship between PCAT and HRP
PCATRCA was significantly higher in patients with HRP compared to patients without HRP (−80.7 ± 6.5 HU vs. −84.2 ± 8.1 HU, p = 0.03 (Figure 2)). PCATLesion was also higher in HRP lesions compared to the highest-grade stenosis lesions in controls (−79.6 ± 7.9 HU vs. −84.2 ± 10.3 HU, p = 0.04). PCATRCA was correlated with PCATLesion (r = 0.513, p < 0.01), but there was no significant difference in PCATRCA and PCATLesion within patients (−81.4 ± 6.8 HU vs. −81.4 ± 9.1 HU, p = 0.98). A visual representation of PCAT attenuation in a patient with HRP and a control patient is shown in Figure 3.
3.3. Relationship between PCAT and ACS
PCATRCA was higher in patients presenting with subsequent ACS compared to those without subsequent ACS (−78.03 HU ± 7.32 vs. −83.3 HU ± 7.29, p = 0.02). PCATLesion was only numerically higher in patients presenting with subsequent ACS compared to those who did not present with ACS (−77.3 HU ± 8.82 vs. −82.4 HU ± 8.93, p = 0.07).
PCATRCA was higher in HRP patients presenting with ACS than HRP patients who did not present with subsequent ACS (−76.8 HU ± 5.69 vs. −82.0 HU ± 6.32, p = 0.03 (Figure 2)). PCATLesion was only numerically higher in patients with HRP who presented with ACS (−76.8 HU ± 9.44 vs. −80.5 HU ± 7.22, p = 0.2).
3.4. Sex-Specific Differences in PCAT
Among all patients, both PCATRCA and PCATLesion were significantly higher in men than in women (PCATRCA: −80.5 ± 7.03 HU vs. −86.1 ± 7.08 HU, p < 0.001; PCATLesion: −79.6 ± 9.06 HU vs. −85.2 ± 7.96 HU, p = 0.02 (Figure 4)). Similar results were observed among patients with HRP (PCATRCA: −78.6 ± 5.97 HU vs. −84.8 ± 5.58 HU, p = 0.002; PCATLesion: −77.7 ± 7.43 HU vs. −83.4 ± 7.52 HU, p = 0.03 (Figure 4)).
3.5. Multivariable Regression Analysis
On multivariable linear regression analysis, sex, HRP and current smoking status were associated with PCATRCA (Table 2) after adjustment for ACS presentation. On multivariable logistic regression, PCATRCA was independently associated with the presence of HRP (Table 3).
3.6. Time-Dependent Analysis
On univariable Cox regression analysis, ACS was significantly associated with HRP presence (OR = 3.79 (95%CI 1.04 to 13.85), p = 0.04) and PCATRCA (OR = 1.09 (95%CI 1.01 to 1.18), p = 0.03), but not with gender (OR = 3.79 (95%CI 0.36 to 3.86), p = 0.78). Additionally, ACS was significantly associated with SSS (OR = 1.12 (95%CI 1.01, 1.24), p = 0.04) and the presence of obstructive CAD (OR = 4.80 (95%CI 1.60, 14.40), p < 0.01), but not by SIS (p = 0.27). No traditional cardiovascular risk factors were significantly associated with ACS (all p > 0.1).
On Kaplan–Meier analysis, patients with HRP harboured significantly greater risk of ACS than patients without HRP (log-rank p = 0.03 (Figure 5)). Patients were also stratified into high- and low-PCATRCA subgroups around a cutoff of the mean PCATRCA within the entire cohort (−82.4 HU ± 7.50). While patients with high-PCATRCA experienced lower percentage survival, this did not achieve significance (log-rank p = 0.08).
4. Discussion
Our study evaluated the association between PCAT attenuation and ACS in patients with HRP features detected on coronary CTA. PCATRCA, a well-validated metric of intracoronary inflammation, is increased in HRP-positive patients who go on to develop ACS compared to those who do not develop major coronary events. Furthermore, HRP presence and PCATRCA is associated with an increased rate of ACS. In addition, we also report sex-specific differences in PCAT attenuation, with increased attenuation being observed in men with HRP compared to women with HRP. The findings of this study highlight differentials in coronary inflammation in the context of ACS, particularly among a patient population at a greater risk of developing events.
The relationship between inflammation and vulnerable atherosclerotic plaque is well-documented in the literature [2,20,21]. Observational studies have established a robust association between HRP and ACS [4,5,17]. Recent evidence arising from the SCOT-HEART study [22] demonstrates the strong predictive value of LAP for fatal and nonfatal myocardial infarction (MI) in a large study population. Moreover, patients within this cohort with the combination of both nonobstructive CAD and LAP burden >4% harboured a sixfold increased risk of MI, highlighting that vulnerable plaque morphology plays a critical role in the development of coronary events independent of plaque-related stenosis.
PCAT studies show that both pan-coronary and lesion-specific inflammation are associated with high-risk lesions in stable CAD [8,14], as well as major coronary events [7,12], indicating potential for PCAT attenuation to detect incipient CAD before the appearance of vulnerable plaque. We report that both HRP presence and PCATRCA were significantly associated with ACS development. Moreover, PCATRCA was higher in patients with HRP who then went on to develop ACS. A number of prior studies have evaluated the relationship between coronary inflammation and ACS in either per-patient [7] or per-lesion forms of PCAT assessment [12,14]. In per-patient analysis, Oikonomou et al. found that increased PCATRCA was predictive of MI in patients with stable CAD [7]. Likewise, Lin et al. found that per-patient PCAT attenuation was associated with AMI and was distinctly higher in these patients compared to stable CAD or control patients [10]. Studies evaluating per-lesion analysis demonstrated increased attenuation around culprit lesions in ACS [12,23] and MI [6,24]. Importantly, Gaibazzi et al. described increased per-vessel PCAT attenuation and HRP characteristics in patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA) and Tako-Tsubo Syndrome (TTS) [24]. The largely non-obstructive nature of vulnerable plaque observed in our study is also evident in the literature [1,2,21,22] and further evidences that HRP features and plaque-specific inflammation may be additive to luminal stenosis in predicting event risk. Indeed, increased PCAT attenuation results in an increased prospective risk of cardiac mortality, among both patients with and without HRP [25]. Nevertheless, we found that only PCATRCA and not PCATLesion were associated with ACS, though both metrics were correlated with one another. A possible explanation may reside in the significant range observed in the duration from coronary CTA to presentation with ACS in these patients; in some cases, PCATLesion may have therefore reflected only a limited degree of inflammation surrounding plaques well before their development into culprit lesions. It is plausible that HRP may represent a series of structural changes appearing later in the inflammatory process which are more acutely related to vulnerability, as a number of studies demonstrate that HRP phenotypes associate with ACS occurring within a year of follow-up [4,26]. Moreover, PCATLesion captures rapid changes in coronary inflammation that occur within weeks of MI [6], further underscoring the dynamic nature of plaque-specific inflammation. In contrast, increased PCATRCA demonstrates a level of inflammation throughout the coronary vasculature that may be present long before localisation to specific sites and culminates in HRP formation. Further studies investigating per-patient and per-lesion forms of PCAT assessment and ACS are required to fully elucidate the inflammatory changes occurring globally within the coronary vasculature and specific to culprit lesions.
We also report significantly increased PCATRCA and PCATLesion in men overall and specifically within groups with HRP. Increased vascular inflammation has been observed in men by means of elevated serum inflammatory biomarkers [27], but sex-specific differences in coronary inflammation remain unclear. Recent studies report increased PCAT attenuation in men compared to women [9,28], and the magnitude of HU difference in these studies was similar to our own findings, although we did not adjust for the influence of age or technical parameters. To the best of our knowledge, ours is the first study that reports increased coronary inflammation shown by both PCATRCA and PCATLesion specifically in men with HRP. As stated previously, the association between HRP and cardiac events is well-documented in the literature [5], but the impact of sex on this association remains uncertain. In a propensity-matched study, Plank et al. found that men had a higher proportion of HRP features and MACE, but the presence of mixed plaque and non-calcified plaque was significantly more prevalent among women [29]. Importantly, numerous studies postulate that middle-aged women may indeed face a higher risk of MACE compared to men when obstructive CAD or HRP is present [29,30], while others demonstrate higher incidence of ACS among men despite a similar prevalence of HRP [31]. While it is clear that sex-specific differences may exist in plaque morphology, elucidating potential differentials in coronary inflammation in the context of vulnerable coronary disease may offer a level of clarity in this area and indicate if there is indeed a heightened risk of major coronary events faced by either sex. The low number of events in our study limited the capacity to further stratify associations between PCAT attenuation and ACS by sex. However, the finding of increased PCATRCA in men with HRP, coupled with the association of PCATRCA with ACS, calls for further investigation into this area to explore the potentially disproportionate risk of major coronary events that men may face with or without HRP.
As atherosclerosis is recognised as a disease of chronic inflammation, the advent of PCAT attenuation as an indirect metric of coronary inflammation provides a useful diagnostic and prognostic tool in evaluating inflammatory risk. This study examines current forms of PCAT assessment in the context of stable CAD patients with HRP, finding that PCAT attenuation is able to detect not only the presence of HRP but the subsequent development of ACS. PCAT therein possesses diagnostic value, enabling indirect assessment of inflammatory risk in individuals with suspected CAD. Incorporation of PCAT assessment into coronary CTA-based risk stratification has been espoused previously [7], and may enhance primary prevention and potential delineation of inflammatory risk prior to plaque formation. Moreover, higher degrees of coronary inflammation shown by increased PCAT would allow for timelier and proactive clinical intervention.
While these findings are novel, this was a small, retrospective, single-centre study. This consequentially limited the number of patients with ACS studied in this cohort, which may have influenced our multivariable analysis of ACS and PCATRCA, and restricted us to only univariable time-dependent analysis of these variables. Development of ACS in patients with CAD would be best studied by large longitudinal studies, though we do report increased PCATRCA even among a small proportion of ACS cases. We performed both PCATRCA and PCATLesion assessment, but the latter may be hampered by factors pertaining to luminal attenuation in the left anterior descending and left circumflex arteries, which decline alongside decreases in luminal diameter and contrast enhancement from ostial to distal segments [32]. Moreover, partial volume averaging due to the spatial resolution limitations of coronary CTA may affect attenuation measurements in pericoronary fat. Finally, data on medical therapy, such as statins and antiplatelet therapy, were not collected for this cohort and were therefore not included in adjusted analyses.
5. Conclusions
PCATRCA and PCATLesion are increased in stable CAD patients with HRP compared to those without HRP. PCATRCA attenuation is higher in patients with HRP who develop ACS and predicts ACS in conjunction with the presence of HRP. PCAT attenuation is higher in men compared to women with HRP. This non-invasive imaging biomarker may identify patients at greater risk of future events, but clinical application of these measures requires further investigation.
Author Contributions
Conceptualization and methodology, R.K.M. and D.T.L.W.; software and validation, A.L. and D.D.; formal analysis and manuscript preparation, J.Y.; manuscript review and editing, A.L., N.N., J.D.C., S.J.N. and D.T.L.W.; project administration, J.D.C. and S.J.N.; supervision, N.N., S.J.N. and D.T.L.W. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Human Research Ethics Committee of Monash.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
No new data were created or analysed in this study. Data sharing is not applicable to this article.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures and Tables
Enlarge this image.Figure 1. Patient selection and study design. Flow chart depicting selection of final study cohort, including patients with HRP matched to patients without HRP. CTA: computed tomography angiography; HRP: high-risk plaque.
Enlarge this image.Figure 2. PCATRCA attenuation by presence of HRP and subsequent presentation with ACS. Bar graphs of per-patient differences in PCAT attenuation in patients with HRP (HRP+) and without HRP (HRP−), and in patients with HRP who developed ACS (HRP+ACS+) and patients with HRP who did not develop ACS (HRP+ACS−). ACS: acute coronary syndrome.
Enlarge this image.Figure 3. Case comparison of per-patient PCAT quantification. Comparison of the RCA of a patient with HRP versus a patient without HRP (control) as shown on coronary CTA. RCA in patient with HRP shown in cross-sectional (A) and longitudinal (D) views, with calcified plaque (yellow) and non-calcified plaque (red) highlighted. Representation of PCAT attenuation of patient with HRP (−75.6 HU) and control (−93.9 HU) shown in cross-sectional (B,C) and longitudinal (E,F) views. Colour map corresponds to CT attenuation in Hounsfield Units (HU) ranging from −190 HU (yellow) to −30 HU (red). Cross-sectional view in patient with HRP shown in panel (B) versus control shown in panel (C). Longitudinal view in patient with HRP shown in panel (E) versus control shown in panel (F). RCA: right coronary artery.
Enlarge this image.Figure 4. PCATRCA attenuation by gender and presence of HRP. Bar graphs of per-patient differences in PCAT attenuation in men (Male) and women (Female), men with HRP (Male, HRP+) and women with HRP (Female, HRP+), and men without HRP (Male, HRP−) and women without HRP (Female, HRP−). ACS: acute coronary syndrome.
Enlarge this image.Figure 5. Survival curve of patients with HRP (red) versus patients without HRP (green).
Patient and plaque characteristics.
| HRP (n = 41) | No HRP (n = 41) | p-Value | |
|---|---|---|---|
| Cardiovascular risk factors | |||
| Age, years | 59.8 (1.45) | 59.2 (1.60) | 0.77 |
| Male sex | 27 (65.9) | 27 (65.9) | 1.0 |
| Hypertension | 16 (39.0) | 15 (36.6) | 0.82 |
| Hypercholesterolaemia | 22 (53.7) | 16 (39.0) | 0.18 |
| Diabetes mellitus | 6 (14.6) | 3 (7.3) | 0.48 |
| Smoker | 7 (17.1) | 4 (9.8) | 0.52 |
| Family history of IHD | 22 (53.7) | 22 (53.7) | 1.0 |
| Obesity | 3 (7.30) | 2 (4.90) | 1.0 |
| ACS | 10 (24.4) | 3 (7.30) | 0.07 |
| Vessel localisation | |||
| LAD | 26 (63.4) | 34 (82.9) | |
| LCx | 4 (9.76) | 2 (4.88) | |
| RCA | 11 (26.8) | 5 (12.2) | |
| Plaque characteristics | |||
| PR | 41 (100) | - | |
| LAP | 24 (58.5) | - | |
| SC | 22 (53.7) | - | |
| Remodelling index * | 1.5 (1.31, 1.73) | - | |
| Obstructive CAD | 15 (36.6) | 1 (2.44) | <0.001 |
| Total plaque volume | 55.6 (6.93) | - | |
| Total plaque burden | 152 (64.6) | - | |
| CCTA segment scores * | |||
| Segment involvement score | 4.5 (3, 6) | 1.0 (0, 4.5) | <0.001 |
| Segment stenosis score | 5.5 (3, 9.5) | 2.0 (0, 6) | 0.001 |
Values are expressed as n (%), or as mean (SD). * Median (IQR).
Table 2Univariable and multivariable linear regression analyses of covariates and PCATRCA.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| Variable | Beta | 95%CI | p-value | Beta | 95%CI | p-value |
| Age | −0.032 | −0.204, 0.140 | 0.712 | |||
| Male sex | 5.631 | 2.367, 8.895 | 0.001 | 5.085 | 1.986, 8.814 | 0.002 |
| Presence of HRP | 3.437 | 0.210, 6.663 | 0.037 | 3.017 | 0.087, 5.947 | 0.044 |
| Presentation with ACS | 5.238 | 0.851, 9.626 | 0.020 | 0.156 | −0.970, 7.338 | 0.131 |
| Hypertension | 0.469 | −2.948, 3.887 | 0.785 | |||
| Hypercholesterolaemia | 1.232 | −2.082, 4.545 | 0.462 | |||
| Diabetes | −0.174 | −5.478, 5.130 | 0.948 | |||
| Smoker | 7.146 | 2.548, 11.744 | 0.003 | 5.733 | 1.396, 10.070 | 0.010 |
| Family history of IHD | 1.366 | −1.945, 4.677 | 0.414 | |||
| Obesity | −2.505 | −9.412, 4.401 | 0.472 | |||
Univariable and multivariable logistic regression analyses of covariates and HRP.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95%CI | p-value | OR | 95%CI | p-value |
| Age | 1.007 | 0.963, 1.053 | 0.766 | |||
| Male sex | 1.0 | 0.401, 2.491 | 1.0 | |||
| PCATRCA | 1.066 | 1.003, 1.134 | 0.041 | 1.064 | 1.000, 1.132 | 0.049 |
| Hypertension | 1.109 | 0.454, 2.710 | 0.820 | |||
| Hypercholesterolaemia | 1.809 | 0.752, 4.352 | 0.186 | 1.723 | 0.701, 4.238 | 0.236 |
| Diabetes | 2.171 | 0.504, 9.350 | 0.298 | |||
| Smoker | 1.904 | 0.512, 7.085 | 0.337 | |||
| Family history of IHD | 1.0 | 0.420, 2.382 | 1.0 | |||
| Obesity | 1.539 | 0.243, 9.733 | 0.647 | |||
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Nicholls, Stephen J 3 ; Wong, Dennis T L 1 1 Monash Cardiovascular Research Centre, Monash University and MonashHeart, Clayton, VIC 3800, Australia;
2 Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA;
3 Monash Cardiovascular Research Centre, Monash University and MonashHeart, Clayton, VIC 3800, Australia;